VZV mRNA Vaccine Services
Varicella-zoster virus (VZV) infection mainly affects the elderly and immunocompromised Currently approved vaccines have significantlimitations: live attenuated vaccines show waning efficacy in the elderly, while the recombinant protein vaccine Shingrix, despite high efficacy,often causes strong side effects. Given itsadvantages, mRNA vaccine technology has emerged as a key solution
Glycoprotein E (gE ) plays a critical role in viral replication cell-to-cellspread . gE is a transmembrane protein . Full-length or truncated version of gE serves as the key target for vaccine development .
Source: Frontiers in Microbiology
RNASci provides VZV gE mRNA Product and Custom Services.
mRNA Product
BNT167 / PF -07915234 (BioNTech/Pfizer) Full-length, truncated or mutated gE antigens
mRNA -1468 (Moderna) Truncated gE antigen (1-573AA, Y569A)
Naked mRNA or mRNA -LNP (SM102 / ALC -0315)
Custom Services
US20230233671A1
US20230374079A1
Pipelines: mRNA-based VZV Vaccine
Vaccine Candidates (Pfizer and BioNTech)
The mRNA shingles vaccine candidates (PF -07915234 , PF -07921186 and PF -07921188 ) encode differentversions of gE on the surface of the varicellazoster virus
More Clinical Pipelines
Pipeline
PF -07915234
PF -07921186
PF -07921188 Full-length, truncated or mutated gE antigens
SYS6017 gE
IN001 gE
JCXH -105* Engineered antigen
ABO -1108 gE
RH110 Not available
Not available Not available
AFN1204
Phase 2 Pfizer
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/2
AFN1213 Not available IND
YKYY026 gE IND
CSPC ( 石石)
Innorna ( 石石)
Immorna (石石石石)
Abogen (石石)
Rhegen (石石石石)
Sinovac (石石石石)
RNAlfa (石石石)
Youcare (石石石石)
Not available Not available IND SIBP CNBG ( 石石石)
Not available Not available IND
* = self-amplifying RNA ( saRNA )
Walvax (石石石石)
Update: Jan 2026